YieldMax TSLA Option Income Strategy ETF (TSLY) Stock Price Today
Key Stats
- -Market Cap
- -Volume
- Income / Options OverlaySector
- $48.2552W High
- $20.4952W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track YieldMax TSLA Option Income Strategy ETF (TSLY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, YieldMax TSLA Option Income Strategy ETF has traded between a low of $20.49 and a high of $48.25, highlighting its annual price range. Buy and sell YieldMax TSLA Option Income Strategy ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Most Recent News
Automattic CEO Matt Mullenweg placed on leave; CFO Mark Davies named interim CEO amid board dispute.
Matt Mullenweg, founder and CEO of Automattic, was placed on a paid leave of absence by the company's board, with CFO Mark Davies appointed as interim CEO. Mullenweg opposed the decision, which was made without giving him time for legal review. The b...
US Treasury tripled bond buybacks but yields rose; Ron Paul warns against trusting Fort Knox gold accounting.
The US Treasury increased its bond buyback ceiling to $6 billion to ease borrowing costs, but 10-year yields still rose to 4.85%. Ron Paul criticized the government's gold accounting at Fort Knox, highlighting the outdated valuation of $42.22 per oun...
Axsome reports strong growth for its CNS drugs AUVELITY, SYMBRAVO, and SUNOSI with new Alzheimer's agitation launch underway.
Axsome Therapeutics, a biopharma company focused on central nervous system (CNS) disorders, reported robust growth for its three commercial products: AUVELITY (for major depressive disorder and Alzheimer's agitation), SYMBRAVO (for migraine), and SUN...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.